DexCom's G7 15 Day wins Health Canada authorization, offering longer wear, high accuracy and smart features for adults with ...

Dexcom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, announced today that Health Canada has authorized the ...

The device demonstrates a MARD of 8% and includes a 12-hour grace period and mobile app compatibility.

Health Canada has authorized the Dexcom G7 15 Day Continuous Glucose Monitoring System for adults with diabetes.

Diabeloop, a pioneer in therapeutic artificial intelligence for diabetes management, today announces that DBLG2 ...

Influencers have found their latest wellness obsession — and, once again, diabetics got there first. First, came GLP-1 drugs.

Heald, a digital metabolic health platform, today announced that consumers who purchase a Dexcom Stelo or Abbott Lingo continuous glucose monitor (CGM) through Heald will now receive complimentary ...

Apple, Samsung, Google, Garmin, and Huawei smartwatches can flag health risks beyond glucose, including hypertension, sleep ...

Smartwatches may transform blood sugar tracking, but today’s advances depend on CGMs, AI, and regulated health tech ...

Check the settings on Apple Watch, Galaxy Watch, Pixel Watch, Huawei Watch, and Garmin that can affect glucose alerts, ...

BTIG analyst Marie Thibault maintained a Buy rating on Dexcom on July 10 and set a price target of $80.00. The company’s shares closed yesterday at $74.96. TipRanks Welcomes a New ETF – NYSE:RANK ...

At 12 months, adults with insulin-treated diabetes had significant improvements in HbA1c and hospitalizations.